×

MyoKardia to Present at Two Upcoming Investor Conferences in November 

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, chief executive officer, will participate in two upcoming investor conferences in November. Following are details for each presentation:

  • 25th Annual Credit Suisse Healthcare Conference, Monday, November 7 at 3:00 PM Mountain Time in Scottsdale, AZ.
  • Stifel 2016 Healthcare Conference, Wednesday, November 16 at 11:45 AM Eastern Time in New York City.

To access live webcasts of these presentations, please visit the “Events & Presentations” page within the Investors & Media section of the MyoKardia website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia website for 30 days following the conference.

About MyoKardia

MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM. MyoKardia’s most advanced product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM and has been evaluated in three Phase 1 clinical trials. MyoKardia is now studying MYK-461 in a Phase 2 PIONEER-HCM pilot study in symptomatic oHCM, for which the FDA has granted MYK-461 Orphan Drug Designation. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry, or SHaRe, a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia believes that SHaRe, currently consisting of data from approximately 10,000 individuals, is the world’s largest registry of patients with heritable cardiomyopathies. MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science. For more information, please visit www.myokardia.com.

Investor Contact: Beth DelGiacco Stern Investor Relations, Inc. 212-362-1200 beth@sternir.com Media Contact: Steven Cooper Edelman 415-486-3264 steven.cooper@edelman.com

Source:MyoKardia, Inc.